Evaluation of the direct and indirect effects of bazedoxifene/conjugated estrogens on sleep disturbance using mediation modeling

Menopause

Volumn 21, Issue 3, 2014, Pages 243-251

  Pinkerton, Joann V ^a   Bushmakin, Andrew G ^b   Racketa, Jill ^b   Cappelleri, Joseph C ^b   Chines, Arkadi A ^b   Mirkin, Sebastian ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b PFIZER INC   (United States)

Author keywords

Bazedoxifene; Conjugated estrogens; Mediation modeling; Sleep; Tissue selective estrogen complex

Indexed keywords

BAZEDOXIFENE PLUS CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MEDIATION MODELING; MENOPAUSAL SYNDROME; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; SLEEP QUALITY; SLEEP TIME; STATISTICAL MODEL; VASOMOTOR DISORDER;

ADULT; DOUBLE-BLIND METHOD; ESTROGENS, CONJUGATED (USP); FEMALE; HOT FLASHES; HUMANS; INDOLES; MEDROXYPROGESTERONE ACETATE; MIDDLE AGED; MODELS, STATISTICAL; PLACEBOS; POSTMENOPAUSE; SLEEP DISORDERS; TREATMENT OUTCOME;

EID: 84896731978     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0b013e31829f05d1     Document Type: Article

References (24)

1. Joffe H, Massler A, Sharkey KM. Evaluation and management of sleep disturbance during the menopause transition. Semin Reprod Med 2010; 28:404-421.
2. Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 2005;3:47.
3. Polo-Kantola P. Sleep problems in midlife and beyond. Maturitas 2011; 68:224-232.
4. Pickar JH, Mirkin S. Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex. Menopause Int 2010;16:121-128.
5. Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/ conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009;92:1025-1038.
6. Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009;16:1116-1124.
7. Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92:1045-1052.
8. Gallagher JC, Lindsay R, Pan K, Mirkin S, Chines A. Effects of bazedoxifene/conjugated estrogens on bone mineral density and bone turnover markers in postmenopausal women: a double-blind, randomized, placebo- and active-controlled phase 3 study [Abstract 1133]. J Bone Miner Res 2011;26:S46.
9. Pickar JH, Yeh I-T, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009;92:1018-1024.
10. Archer DF, Lobo RA, Pan K, et al. Safety and tolerability of bazedoxifene/conjugated estrogens in postmenopausal women: findings from a 1-year, randomized, placebo- and active-controlled, phase 3 trial [Abstract P-25]. Menopause 2011;18:1355-1356.
11. Pinkerton JV, Chines AA, Racketa J, Mirkin S. Bazedoxifene/conjugated estrogens (BZA/CE): effect on sleep parameters in postmenopausal women [Abstract P-53]. Menopause 2010;17:1237-1238.
12. Utian W, Yu H, Bobula J, Mirkin S, Olivier S, Pickar JH. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas 2009;63:329-335.
13. Pinkerton JV, Pan K, Abraham L, Racketa J, Chines AA, Mirkin S. Effects of bazedoxifene/conjugated estrogens on sleep parameters and health-related quality of life in postmenopausal women [Abstract S-13]. Menopause 2011;18:1346.
14. Iacobucci D. Mediation Analysis. Los Angeles, CA: Sage, 2008.
15. MacKinnon DP. Introduction to Statistical Mediation Analysis. New York, NY: Lawrence Erlbaum Associates, 2008.
16. Guidozzi F. Sleep and sleep disorders in menopausal women. Climacteric 2013;16:214-219.
17. Archer DF, Lewis V, Carr BR, Olivier S, Pickar JH. Bazedoxifene/ conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril 2009;92:1039-1044.
18. The North American Menopause Society. The 2012 hormone therapy position statement of The North American Menopause Society. Menopause 2012;19:257-271.
19. Shaver JL. Positive effects of hormone therapy on sleep: compelling evidence or not? Menopause 2011;18:1157-1159.
20. Ockene JK, Barad DH, Cochrane BB, et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA 2005;294:183-193.
21. Tom SE, Anderson ML, Landis CA, et al. Sleep problems after short-term hormone therapy suspension: secondary analysis of a randomized trial. Menopause 2011;18:1184-1190.
22. Tranah GJ, Parimi N, Blackwell T, et al. Postmenopausal hormones and sleep quality in the elderly: a population based study. BMC Womens Health 2010;10:15.
23. Natale V, Albertazzi P, Missiroli N, Pedrini D, Salgarello M. Effects of raloxifene on mood, sleep, libido and cognitive function in postmenopausal healthy women: a pilot study. Maturitas 2004;48:59-63.
24. Carranza-Lira S, Gooch AL, Saldivar N, Osterwalder MS. Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses. Int J Fertil Womens Med 2007; 52:93-96.